Gerald Spöttl
Perifosine-mediated Akt inhibition in neuroendocrine tumor cells: role of specific Akt isoforms
Zitzmann K, Vlotides G, Brand S, Lahm H, Spöttl G, Göke B, Auernhammer C. Perifosine-mediated Akt inhibition in neuroendocrine tumor cells: role of specific Akt isoforms. Endocr Relat Cancer 2012; 19:423-34.
May 24, 2012Perifosine-mediated Akt inhibition in neuroendocrine tumor cells: role of specific Akt isoforms
May 24, 2012Endocr Relat Cancer 2012; 19:423-34
Zitzmann Kathrin, Vlotides George, Brand Stephan, Lahm Harald, Spöttl Gerald, Göke Burkhard, Auernhammer Christoph J
Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease
Zitzmann K, Rüden J, Brand S, Göke B, Lichtl J, Spöttl G, Auernhammer C. Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. Cancer Lett 2010; 295:100-9.
Mar 30, 2010Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease
Mar 30, 2010Cancer Lett 2010; 295:100-9
Zitzmann Kathrin, Rüden Janina von, Brand Stephan, Göke Burkhard, Lichtl Jennifer, Spöttl Gerald, Auernhammer Christoph J
SOCS1 silencing enhances antitumor activity of type I IFNs by regulating apoptosis in neuroendocrine tumor cells
Zitzmann K, Brand S, De Toni E, Baehs S, Göke B, Meinecke J, Spöttl G, Meyer H, Auernhammer C. SOCS1 silencing enhances antitumor activity of type I IFNs by regulating apoptosis in neuroendocrine tumor cells. Cancer Res 2007; 67:5025-32.
May 15, 2007SOCS1 silencing enhances antitumor activity of type I IFNs by regulating apoptosis in neuroendocrine tumor cells
May 15, 2007Cancer Res 2007; 67:5025-32
Zitzmann Kathrin, Brand Stephan, De Toni Enrico N, Baehs Sebastian, Göke Burkhard, Meinecke Jennifer, Spöttl Gerald, Meyer Heinrich H H D, Auernhammer Christoph J
The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells
Zitzmann K, De Toni E, Brand S, Göke B, Meinecke J, Spöttl G, Meyer H, Auernhammer C. The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology 2007; 85:54-60.
Feb 19, 2007The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells
Feb 19, 2007Neuroendocrinology 2007; 85:54-60
Zitzmann Kathrin, De Toni Enrico N, Brand Stephan, Göke Burkhard, Meinecke Jennifer, Spöttl Gerald, Meyer Heinrich H D, Auernhammer Christoph J
Novel interferon-lambdas induce antiproliferative effects in neuroendocrine tumor cells
Zitzmann K, Brand S, Baehs S, Göke B, Meinecke J, Spöttl G, Meyer H, Auernhammer C. Novel interferon-lambdas induce antiproliferative effects in neuroendocrine tumor cells. Biochem Biophys Res Commun 2006; 344:1334-41.
Apr 24, 2006Novel interferon-lambdas induce antiproliferative effects in neuroendocrine tumor cells
Apr 24, 2006Biochem Biophys Res Commun 2006; 344:1334-41
Zitzmann Kathrin, Brand Stephan, Baehs Sebastian, Göke Burkhard, Meinecke Jennifer, Spöttl Gerald, Meyer Heinrich, Auernhammer Christoph J